Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01229449 · ClinicalTrials.gov registry record · Phase 3
Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study
A Phase 3 study, sponsored by Reckitt Benckiser.
- Completed
- Registry status
- Phase 3
- Development phase
- 678
- Enrollment target
NCT01229449 is a Phase 3 study that has completed, run by Reckitt Benckiser. The registered enrollment target is 678 participants.
The verdict
NCT01229449, a Phase 3 study, has completed, sponsored by Reckitt Benckiser.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 678 participants
- Enrollment target
Study Summary
The objective is to assess the efficacy and tolerability of a combination of 400 mg ibuprofen plus 1000 mg acetaminophen, 200 mg ibuprofen plus 500 mg acetaminophen compared with Nurofen Plus® and Panadeine® Extra.
Interventions
- DRUG Placebo
- DRUG Ibuprofen/acetaminophen
- DRUG Ibuprofen/acetaminophen (higher dose)
- DRUG Nurofen Plus®
- DRUG Panadeine® Extra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 678 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01229449
The ClinicalTrials.gov registry entry for NCT01229449 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 678 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Reckitt Benckiser, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01229449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01229449 about?
NCT01229449 is a clinical study titled "Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study". The objective is to assess the efficacy and tolerability of a combination of 400 mg ibuprofen plus 1000 mg acetaminophen, 200 mg ibuprofen plus 500 mg acetaminophen compared with Nurofen Plus® and Panadeine® Extra.
What is the current status of trial NCT01229449?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 678 participants. The study started on 2009-01. Estimated completion is 2009-09.
What interventions are being tested in trial NCT01229449?
The interventions under investigation include: Placebo (DRUG), Ibuprofen/acetaminophen (DRUG), Ibuprofen/acetaminophen (higher dose) (DRUG), Nurofen Plus® (DRUG), Panadeine® Extra (DRUG).
Who is sponsoring clinical trial NCT01229449?
This trial is sponsored by Reckitt Benckiser, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.